Pfizer announced a projected $32 billion in revenue this year from its publicly funded COVID-19 vaccine. 

New York, February 9 (RHC)-- Pfizer announced a projected $32 billion in revenue this year from its publicly funded COVID-19 vaccine.  That’s just part of Pfizer’s overall projected revenue of around $100 billion in 2022, with another $22 billion coming from the sale of its COVID pill Paxlovid. 

Pfizer has refused to share its technology with other countries in desperate need of vaccines.  Oxfam said in response to Pfizer’s financial report: “Thousands of people in Africa are dying every day from COVID because companies like Pfizer have prioritized profits over saving lives. … No corporations should decide who lives and who dies.”

In other vaccine news, Johnson & Johnson has halted production of its coronavirus vaccine.  The Dutch plant making the only usable doses of the shot switched over to production of an experimental vaccine unrelated to COVID.  The pause, which started at the end of last year, is expected to last a few months.  Many African nations, as well as the COVAX distribution program, rely heavily on J&J’s one-dose vaccine.